

# Merkel Cell Carcinoma - Pipeline by Global Drug Profiles, H2 2017

PUNE, MAHARASHTRA, INDIA, February 26, 2018 /EINPresswire.com/ --  
Merkel Cell Carcinoma

## Overview

Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery.



**AKASH ANAND**  
ASST.MANAGER - BUSINESS DEVELOPMENT

✉ sales@wiseguyreports.com  
☎ Ph: +1-646-843-9312 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>  
🐦 <http://twitter.com/WiseGuyReports>  
📘 <http://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Merkel Cell Carcinoma

Click here for sample report @ <https://www.wiseguyreports.com/sample-request/2740083-merkel-cell-carcinoma-pipeline-review-h2-2017>

## Major Key Players:

Apcure SAS

BeiGene Ltd

Genentech Inc

Immune Design Corp

Merck & Co Inc

Ono Pharmaceutical Co Ltd

Philogen SpA

Tarveda Therapeutics Inc

## Major Highlight

Pharmaceutical and Healthcare latest pipeline guide Merkel Cell Carcinoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Merkel Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 13, 10 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Merkel Cell Carcinoma pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

.Continued

For Detailed Reading Please visit @ <https://www.wiseguyreports.com/reports/2740083-merkel-cell-carcinoma-pipeline-review-h2-2017>

## About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

[sales@wiseguyreports.com](mailto:sales@wiseguyreports.com)

[www.wiseguyreports.com](http://www.wiseguyreports.com)

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent

WiseGuy Research Consultants Pvt. Ltd.

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/434133339>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.